Semi-synthetic route for the preparation of paclitaxel,...

Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C549S511000

Reexamination Certificate

active

07847111

ABSTRACT:
A semisynthetic route has been provided in the preparation of docetaxel and paclitaxel. This new process involves the conversion of 9-dihydro-13-acetylbaccatin III to docetaxel and paclitaxel by the step of converting 9-dihydro-13-acetylbaccatin III into 7-O-triethylsilyl-9,10-diketobaccatin III, and adding docetaxel and paclitaxel side chain precursors, respectively, to form a new class of taxane intermediates, such as 7-O-triethylsilyl-9,10-diketodocetaxel and 7-O-triethylsilyl-9,10-diketopaclitaxeltaxel. These new intermediates then by a series reduction, acetylation of the 10-hydroxyl position for paclitaxel and finally deprotection to yield docetaxel and paclitaxel, the most important anti-cancer drugs.

REFERENCES:
patent: 4924011 (1990-05-01), Denis et al.
patent: 5352806 (1994-10-01), Gunawardana et al.
patent: 5440056 (1995-08-01), Klein et al.
patent: 5530020 (1996-06-01), Gunawardana et al.
patent: 5594157 (1997-01-01), Gunawardana et al.
patent: 5616740 (1997-04-01), Klein et al.
patent: 5763477 (1998-06-01), Duvvuri et al.
patent: 6066747 (2000-05-01), Holton et al.
patent: 6175023 (2001-01-01), Liu
patent: 6197981 (2001-03-01), Liu
patent: 6222053 (2001-04-01), Zamir et al.
patent: 6232477 (2001-05-01), Bouchard et al.
patent: 6331635 (2001-12-01), Bouchard et al.
patent: 6384071 (2002-05-01), Bouchard et al.
patent: 6495701 (2002-12-01), Matsubara
patent: 6552205 (2003-04-01), Holton et al.
patent: 6576777 (2003-06-01), Zamir et al.
patent: 6593482 (2003-07-01), Bouchard et al.
patent: 6706896 (2004-03-01), Holton et al.
patent: 6710191 (2004-03-01), Holton et al.
patent: 6734304 (2004-05-01), Weintritt
patent: 6784304 (2004-08-01), Tothathil et al.
patent: 6812356 (2004-11-01), Findlay et al.
patent: 6872842 (2005-03-01), Holton et al.
patent: 6878834 (2005-04-01), Holton et al.
patent: 7202370 (2007-04-01), Naidu
patent: 2215682 (1996-09-01), None
patent: 2231837 (1997-03-01), None
patent: 2188190 (1998-04-01), None
patent: 2307548 (1998-11-01), None
patent: 2403429 (2001-09-01), None
patent: 2444693 (2004-03-01), None
patent: 0400971 (1990-12-01), None
patent: 0428376 (1991-05-01), None
patent: WO 2005/030150 (2005-04-01), None
patent: WO 2007/073383 (2007-06-01), None
patent: WO 2005/075870 (2007-07-01), None
Appendino et al, Terta. Let. vol. 38 No. 24 pp. 4273-4276 (1997) “Synthesis and Evaluation of C-Seco Paclitaxel Annalogues”.
Appendino G et al: “The Reductive Fragmentation of 7-Hydroxy-9,10-dioxotaxoids” European Journal Oforganic Chemistry, Wiley-VCH Verlag, Weinheim, DE, No. 22, Jan. 1, 2003, pp. 4422-4431, XP002486097 ISSN: 1434-193X scheme 4; p. 4426.
Denis J-N: “A Highly Efficient˜Practical 7-14 Approach Tonatural Taxol” Journal of the American Chemical Society, vol. 110, No. 17, 1988, pp. 5917-5920, XP000654163; ISSN: 0002-7863 ; p. 5918; compound 4.
EPO—Supplementary European Search Report—EP 07719967—(EPO Form 1503 03.82)—Nov. 2, 2009—11 pages.
PCT—International Search Report (ISR)—PCT/CA2007/001051 (Form PCT/ISA/210)—Oct. 4, 2007—4 pages.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Semi-synthetic route for the preparation of paclitaxel,... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Semi-synthetic route for the preparation of paclitaxel,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Semi-synthetic route for the preparation of paclitaxel,... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4197158

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.